RANDOLPH VALENZUELA: Open Payments
NPI 1447938337 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$338 in 13 payments from 9 companies in 2025. Trend: 2023 $110 · 2024 $326 · 2025 $338
Food & beverage: $338
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Lilly USA, LLC | 4 | $67 |
| Exact Sciences Corporation | 2 | $31 |
| PFIZER INC. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Abbott Laboratories | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: BREZTRI, JARDIANCE, Cologuard Collection Kit, MOUNJARO, PAXLOVID, TRELEGY ELLIPTA, FREESTYLE LIBRE 3, GVOKE HYPOPEN.
Industry payments across TX — which companies pay providers there.
